comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-27 14:10:39 - browse：1

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Innovation in antibiotics is ailing. 'Brain drain' may kill it

WSS

With trial win, GSK could get blood cancer drug back on market

Meta's Zuckerberg and Chan on track to put $50 billion into science

Telehealth options flood the market as retailers push virtual care

With trial win, GSK could get blood cancer drug back on market

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

BMI, flaws aside, is found to be useful estimate of body fat in youth

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Apple is now the first public company to be valued at $3 trillion

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Dobbs anniversary: the lost opportunity of abortion as health care

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

How one medical school became remarkably diverse

Emergency medicine has repudiated 'excited delirium.' Now what?

Hollywood unions extend contract negotiations for actors

At ASCO, AstraZeneca reports strong data for breast cancer drug

Continuity nursing helped my family in our darkest PICU moments

First Opinion Podcast: How to protect health care in times of war

hotspot

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Intellia reports positive results for its CRISPR

NIH documents show early flaws of $1.6 billion long Covid program

Kaiser's Risant Health gobbled up Geisinger. Who is next?

FDA has safety concerns on CRISPR

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Wikipedia

Wikipedia

hotspot

entertainment